Mylan CEO to face House hearing for EpiPen price hike — 4 insights

Mary Rechtoris -   Print  |

Next week, the House Oversight will hold a hearing for Mylan CEO Heather Bresch to answer questions regarding EpiPen's price hike, according to The Hill.

Here are four insights:


1. Since Mylan acquired and began selling EpiPen nearly 10 years ago, the drug's price has spiked almost 400 percent.


2. In August, EpiPen said it would offer a generic product, which carries a $300 list price. Mylan is also working with school district and patient advocacy groups. New York Attorney General Eric Schneiderman is investigating the program in which Mylan provided 700,000 free EpiPens.


3. In a joint statement, House  Chairman Jason Chaffetz (R-Utah) and Rep. Elijah Cummings (D-Md.), said, "We look forward to receiving answers next week from Mylan about its dramatic price hike for this life-saving medication."


4. An FDA official, Doug Throckmorton, MD, will also testify at the hearing. Chairman Chaffetz and Rep. Cummings said, "We also plan to examine ways to encourage greater competition in the EpiPen market and to speed FDA's approval of acceptable new generic applications."


More articles on practice management:
As medical industry changes, face-to-face sales become a thing of the past: 5 takeaways
Tennessee Physicians and NPs argue over scope of practice laws: 8 things to know
The AMA's take on Dr. Oz & physicians in the spotlight — 5 things to know

© Copyright ASC COMMUNICATIONS 2021. Interested in LINKING to or REPRINTING this content? View our policies here.

Featured Webinars

Featured Whitepapers